MK-677 (Ibutamoren)
Overview
MK-677 (Ibutamoren) is a non-peptide, orally active agonist of the growth-hormone-secretagogue receptor (GHSR-1a) — the ghrelin receptor. Although it sits in this “growth peptides” category, it is a small molecule, not a peptide. By mimicking ghrelin it stimulates the body’s own pulsatile growth-hormone release and raises IGF-1, and it has been studied for lean mass, bone density and metabolic endpoints. It is a research compound.
Chemical Profile
| Property | Value |
|---|---|
| CAS number | 159634-47-0 (free base) |
| Class | Non-peptide GHSR-1a agonist (ghrelin mimetic) |
| Molecular formula | C₂₇H₃₆N₄O₅S (free base) |
| Molecular weight | 528.66 g/mol (free base) |
| Chemical type | Small molecule (spiro-indoline), not a peptide |
| Purity (HPLC) | ≥ 98% |
| Appearance | White to off-white powder |
- Class
- Non-peptide GHSR-1a agonist
- Originator
- Merck & Co.
- Research status
- Investigational; GH / metabolic research
- Study route
- Oral
- Half-life
- ≈ 24 h (once-daily)
- Key feature
- Orally active, long-acting GH secretagogue
Mechanism of Action
MK-677 binds the ghrelin receptor (GHSR-1a) on the pituitary and hypothalamus, reproducing ghrelin’s signal to release growth hormone. Because it amplifies the body’s own GH pulses rather than supplying GH directly, it is studied as a way to raise GH and IGF-1 while keeping the natural pulsatile pattern. Its oral activity and long half-life set it apart from the injectable peptide secretagogues.
| Component | Detail |
|---|---|
| Primary target | GHSR-1a (ghrelin receptor) |
| Receptor class | G-protein-coupled receptor |
| G-protein coupling | Gαq/11 → PLC → IP₃/DAG → intracellular Ca²⁺ |
| Pituitary effect | Direct stimulation of somatotroph GH secretion |
| Hypothalamic effect | Enhances GHRH, blunts somatostatin |
| IGF-1 | Sustained increase in circulating IGF-1 |
| System | Studied effect |
|---|---|
| Muscle | Increased lean body mass (GH/IGF-1) |
| Bone | Increased bone-mineral density in models |
| Adipose | GH-mediated lipolysis |
| Sleep | Enhanced slow-wave sleep |
| Appetite | Increased (ghrelin-receptor activation) |
Pharmacology
| Parameter | Value |
|---|---|
| Half-life (t½) | ≈ 24 h |
| Bioavailability (oral) | > 60% (estimated) |
| Time to peak (Tmax) | ≈ 1–2 h |
| Protein binding | > 99% (albumin, α₁-acid glycoprotein) |
| Metabolism | Hepatic (CYP3A4) |
| Route of administration | Oral |
| Elimination | Renal and fecal |
Research Evidence
MK-677 has both preclinical and clinical literature spanning GH physiology, body composition and bone. Representative studies and their focus are named below; specific numerical outcomes are not restated here as claims.
| Study type | Research focus | Reference |
|---|---|---|
| Rat pituitary cells | Dose-dependent GH release (GHSR agonism) | Jacks T, et al. |
| Healthy-volunteer study | 24-h GH AUC and IGF-1 | Chapman IM, et al. |
| Elderly, 2-year study | Lean body mass and bone density | Nass R, et al. (2008) |
| Obese subjects | Visceral fat and insulin sensitivity | GH-secretagogue literature |
Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):
| Reported direction / finding | Context | Reference |
|---|---|---|
| Increased 24-h GH and IGF-1 | healthy-volunteer study | Chapman IM et al. |
| Increased lean mass and bone density over 2 years | older adults | Nass R et al., 2008 |
| Preserved GH pulsatility with oral, once-daily dosing | GH-physiology studies | MK-677 literature |
For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.
Dosing & Handling Reference
Handling parameters for laboratory research. Not dosing guidance for human use.
| Parameter | Reference value |
|---|---|
| Research dose range (literature) | ≈ 10–25 mg daily (oral), in study protocols |
| Form | Oral (small molecule; no reconstitution) |
| Storage | Room temperature, desiccated, protected from light |
| Do not use | If material shows discoloration or degradation |
Safety Profile
Published research observations, provided for reference only. This material is not for human or veterinary use.
| Category | Published observations |
|---|---|
| Most common | Increased appetite, transient fatigue, mild fluid retention |
| Metabolic | Transient insulin resistance / glucose elevation in some studies |
| Endocrine | GH / IGF-1 elevation; mild cortisol change reported |
| Interactions | CYP3A4 substrate — interactions with CYP3A4 inhibitors/inducers |
| Status | For research use only; not for human or veterinary application |
Physicochemical Properties
| Property | Value |
|---|---|
| Physical state | White to off-white powder |
| Solubility (water) | Poor; soluble in DMSO / organic solvents |
| logP (octanol/water) | ≈ 3.2 (lipophilic) |
| Chemical class | Spiro-indoline small molecule |
| Stability | Stable at room temperature when desiccated and dark |
Synthesis & Manufacturing
Unlike the peptide secretagogues in this category, MK-677 is made by multi-step organic synthesis (it is a spiro-indoline small molecule), then purified by chromatography and characterised by NMR and mass spectrometry rather than by peptide methods.
- Multi-step solution-phase organic synthesis
- Chromatographic purification to research grade
- Identity confirmed by NMR and mass spectrometry; purity by HPLC
Analytical Methods
As a small molecule (not a peptide), MK-677 is characterised by the standard organic-chemistry panel — NMR and mass spectrometry for structure, HPLC for purity — rather than by peptide-specific assays.
| Method | Purpose | Typical result |
|---|---|---|
| RP-HPLC (C18, UV 220/254 nm) | Purity | ≥ 98% |
| ¹H / ¹³C NMR | Structure confirmation | Consistent with the spiro-indoline structure |
| ESI-MS / HRMS | Identity / accurate mass | [M+H]⁺ ≈ 529 Da |
| IR spectroscopy | Functional-group confirmation | Consistent with amide / sulfonyl groups |
| Melting point / DSC | Identity / polymorph | Sharp, characteristic |
| Karl Fischer | Water content | Low (per specification) |
| Residual solvents (GC) | ICH Q3C limits | Within limits |
| Heavy metals / ICP-MS | Elemental impurities | Within limits |
Representative HPLC method:
- Column: C18, 5 µm, 250 × 4.6 mm
- Mobile phase: aqueous buffer / acetonitrile gradient · Flow rate: 1.0 mL/min
- Detection: UV 220 nm (and 254 nm) · Identity confirmed by NMR + HRMS
Stability Data
| Condition | Duration | Result |
|---|---|---|
| Solid, 2–8°C, desiccated, dark | ≥ 36 months | Stable |
| Solid, room temperature, desiccated | ≥ 24 months | Stable |
| Solid, 40°C (accelerated) | 3 months | No significant degradation |
| In DMSO / organic solvent, −20°C | Months | Stable if kept cold and dark |
| In aqueous solution | Limited | Poorly water-soluble; prepare fresh |
| Photostability (ICH Q1B) | Standard | Protect from light |
- The free base is a stable crystalline solid; keep desiccated and protected from light.
- It is only sparingly water-soluble — for in-vitro work dissolve in DMSO first, then dilute; prepare aqueous dilutions fresh.
Selected References
- Patchett AA, et al. Design and biological activities of L-163,191 (MK-0677), an orally active growth-hormone secretagogue. Proceedings of the National Academy of Sciences.
- Chapman IM, et al. Oral administration of the growth-hormone secretagogue MK-677 increases GH and IGF-1. Journal of Clinical Endocrinology & Metabolism.
- Nass R, et al. Effects of an oral ghrelin mimetic on body composition in healthy older adults. Annals of Internal Medicine, 2008.
Quality & Supply
- HPLC ≥ 98% purity with a Certificate of Analysis per batch
- Identity confirmed by NMR and mass spectrometry
- Research quantities through to bulk, with worldwide delivery
- Custom quantities and packaging on request
Need MK-677 — sample or bulk?
HPLC-verified, COA per batch. Tell us the quantity you need.
